1 Department of Cardiology, Boston Children’s Hospital, Boston, MA.

2 Department of Pediatrics, Harvard Medical School, Boston, MA.

3 Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, MI.

*See also p. 499.

Dr. Alexander’s institution received funding from the National Institute for Child Health and Development (R13HD104432 Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative), the U.S. Food and Drug Authority (FDA) (“Creating a Framework for a National Adaptive Platform Trial to Evaluate Pediatric Medical Devices” supported by a FDA Grant Number U01FD004979/U01FD005978 University of California San Francisco (UCSF)-Stanford Center of Excellence in Regulatory Sciences and Innovation) and U.S. Department of Defense W81XWH2210301; she received funding for Endpoint Adjudication of Novartis Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric Heart Failure (PANORAMA-HF) trial; and he received funding from Novartis. Dr. Barbaro’s institution received funding from the National Heart, Lung, and Blood Institute (K12 HL138039); he disclosed that he is Extracorporeal Life Support Organization Board of Directors, Member Pedi-Extracorporeal Membrane Oxygenation, Co-Chair; and he received support for article research from the National Institutes of Health. Dr. Habet has disclosed that she does not have any potential conflicts of interest.